Study: Debio 4326-301: An open-label, single-arm, multi-center, Phase 3 study on the efficacy,
safety, and pharmacokinetics of Debio 4326, a triptorelin 12-month formulation, in
pediatric participants who are receiving gonadotropin-releasing hormone agonist therapy
for central precocious puberty
Please Select Your Affiliation with CU Anschutz
Thank you for expressing your interest in a research study and for taking the time to provide your information.
By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 3 to 5 business days.
Please understand that:
- The research team will need to determine whether you are eligible for the study. Clicking 'Submit' does not enroll you into the study, or guarantee that you qualify for the study.
- It is always your choice to participate.
Thanks again. Volunteers such as yourself are at the core of our work.
